Clinical Trials Browser

Clear-cell metastatic renal cell carcinoma × CTLA-4 Antigen × 30 days × Clear all

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell